

**Reversal of elevated urinary
N-acetyl- β -glucosaminidase in an asymptomatic,
severe form of glomerulonephropathy
with vasodilators.**

Kanit Buranasiri*
Pornpimol Saleekul* Prasit Futrakul***
Sopit Thamaree**** Pornchai Kingwatanakul**
Rachan Sensirivatana*** Dhevi Watana***
Narisa Futrakul** Sophon Panichpun*****

Buranasiri K, Saleekul P, Futrakul P, Thamaree S, Kingwatanakul P, Sensirivatana R, Watana D, Futrakul N, Panichpun S. Reversal of elevated urinary N-acetyl- β -glucosaminidase in an asymptomatic, severe form of glomerulonephropathy with vasodilators. Chula Med J 1993 Jan; 37(1): 21-27

Tubular enzymuria determined as urinary N-acetyl- β -glucosaminidase has been noted to be elevated in both mild and severe forms of NS. During remission, normal value of urinary NAG was observed in mild form of NS, whereas high values of NAG were still observed in one-third of the cases in the severe form of NS. Further reduction of urinary NAG could be achieved with therapeutic vasodilators in this latter group of patients-suggesting a hemodynamically mediated trigger being responsible for the tubular injury.

Key words: *Glomerulonephritis, Tubular enzymes, Vasodilators.*

Reprint request : Buranasiri K, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Receiver for publication. October 14, 1992.

* Department of Biochemistry, Faculty of Medicine, Chulalongkorn University.

** Department of Medicine, Siriraj Medical School Hospital.

*** Department of Pediatrics, Faculty of Medicine, Chulalongkorn University.

**** Department of Pharmacology, Faculty of Medicine, Chulalongkorn University

***** Department of Medicine, Ramathibodi Hospital.

ชนิษฐ บุรณศิริ, พรพิมล สาลีกุล, ประสิทธิ์ พุตระกูล, โสภิต ธรรมอารี, พรชัย กิ่งวัฒนากุล, รัชณี เชนศิริวัฒนา, เทวี วัฒนา, นริสา พุตระกูล, โสภณ พานิชพันธ์. การแก้ไขระดับเอ็น-อะเซทิล-บีต้า-กลูโคซามินิเดส ที่สูงผิดปกติในปัสสาวะของผู้ป่วยไตอักเสบอย่างรุนแรงที่ไม่มีอาการ ด้วยยาออกฤทธิ์ขยายหลอดเลือด จุลาลงกรรมเวชสาร 2536 มกราคม; 37(1): 21-27

การศึกษาในผู้ป่วยไตอักเสบชนิดเนฟโรสิส พบค่า *N-acetyl-β-glucosaminidase* สูงผิดปกติในปัสสาวะ ขณะที่กำลังมีไข้ขาวร่ำมาก ความผิดปกตินี้จะหายไปเองในผู้ป่วยเนฟโรสิสที่ตอบสนองดีต่อยา *Prednisolone* แต่ในผู้ป่วยที่มีลักษณะโรครุนแรงและคือต่อยา เช่น พวก *FSGS*, *MPGN* หรือ *DPGN* ความผิดปกติของ *N-acetyl-β-glucosaminidase* อาจยังคงสูงอยู่ได้ในปัสสาวะในขณะที่ไม่มีอาการแสดงของโรค ความผิดปกติดังกล่าวสามารถแก้ไขได้โดยการให้ยาที่ออกฤทธิ์ขยายหลอดเลือด คณะผู้วิจัยให้สมมติฐานว่า ความผิดปกติในการทำงานของเซลล์บุท่อไตน่าจะมีสาเหตุจากภาวะการไหลเวียนของเลือดในไตที่ผิดปกติ

Tubular dysfunctions such as renal tubular acidosis, tubular enzymuria, tubular transporting defect, impaired maximal tubular concentrating mechanism and acidification have been well substantiated in various glomerulonephrities particularly in those patients associated with severe form commonly destined for chronic renal insufficiency—namely focal segmental glomerulosclerosis (FSGS), membranoproliferative glomerulonephritis (MPGN) and diffusely proliferative glomerulonephritis (DPGN).⁽¹⁻¹⁸⁾ In addition, tubulointerstitial fibrosis has recently been recognized as a pivotal risk factor of progressive process of glomerulotubulo-interstitial injury in this severe form of glomerulopathy.⁽¹⁹⁻²⁴⁾ The mechanism for such development of tubular dysfunction and its relationship to the tubulo-interstitial fibrosis has still remained to be further elucidated. Nonetheless, the hemodynamically mediated glomerulo-tubular injury has been implicated in this progressively prone glomerulonephritis in which much reduction in peritubular capillary blood flow secondary to the increase in intrarenal resistance with particularly preponderant vasoconstriction at the efferent arteriole has been observed.⁽²⁵⁻²⁷⁾

The spatial interrelationship between tubular enzymuria and the altered intrarenal hemodynamics is needed to be established. If this will be the case, therefore, therapeutic implementation aiming to improve the abnormal intrarenal hemodynamics with vasodilators would provide some significant impact upon the status of tubular enzymuria and thus, such objective would form the basis of our present study.

Material and Method

Initial and subsequent urine samples from 59 nephrotic patients were subjected to N-acetyl- β -glucosaminidase (NAG) study according to the colorimetric method as described by Maruhn⁽²⁸⁾ and Werner⁽²⁹⁾ and the study in adult subjects was reported earlier/ in this journal.⁽³⁰⁾ Of these 59

nephrotics, 29 were classified clinically as mild form characterized by either therapeutic remission with prednisolone or histopathologically proven as minimal-change or mild mesangial proliferative GN., 30 were considered as a clinically severe subset with therapeutic resistant to the conventionally-treated with prednisolone and the histopathologic proven as FSGS, DPGN or MPGN.

Intrarenal hemodynamics had been assessed in some of these nephrotic patients and the detail of the study had been reported elsewhere.^(18,25,32) The values of urinary NAG were subjected to the statistical analysis of variance using student Newman Keuls Test and using the Nonparametric Method by means of Wilcoxon Matched-pairs Signed-ranks test for the 9 nephrotics under therapeutic comparison,^(31,32) the difference was significant statistically at the 0.05 level.

Therapeutic regimen

A combination of vasodilators consisting of dipyridamole 15 mg/kg/day, calcium channel blocker mainly nifedipine 1-3 mg/kg/day and angiotensin convertase inhibitor mainly enalapril 0.5-2 mg/kg/day was additionally prescribed to all of the 9 nephrotics who were clinically unresponsive to prednisolone therapy.

Results

Elevated levels of NAG were observed in both forms of NS during active proteinuria. Normalisation of urinary NAG value was documented in the mild form of NS during remission. In contrast in the severe form of NS during follow-up, partial reduction of urinary NAG was observed in 2/3 while in more than one-third it still remained highly elevated.(Table 1) However, further reduction of urinary NAG toward normal was substantiated following therapy with vasodilators. (Table 2)

Table 1. Summarised the study of urinary N-acetyl- β -glucosaminidase in mild and severe forms of nephrotic syndrome during both active proteinuria and remission.

Group	No. subjects	NAG unit/gm creatinine
severe NS (active)	n = 17	62.0 \pm 56.3
severe NS (follow-up)	n = 30	10.0 \pm 11.2
Mild NS (active)	n = 29	68.4 \pm 69.9
Mild NS (remission)	n = 21	2.6 \pm 3.0

* Statistical significance at $p < 0.05$

Table 2. Demonstrated the pre-and post-treatment values of urinary N-acetyl- β -glucosaminidase (NAG) in the 9 nephrotics with persistently elevated urinary NAG.

	NAG (unit/gm creatinine)
Pre-treatment	28.2* \pm 16.5
Post-treatment	10.4 \pm 8.1

* Statistical significance at $p < 0.05$

Discussion

Persistently elevated level of urinary NAG was demonstrated in one-third of the cases in severe form of NS of which rendered a supportive view that a certain degree of progressive process of renal tubular injury had still existed through the convalescent stage. Further supports to this view are the previous notions of abnormal expression of intercellular adhesion molecule-1 and aberrant expression of HLA-DQ and -DP antigens on proximal tubular epithelial cells in various form of glomerulonephritis associated with interstitial inflammation,⁽³³⁻³⁵⁾ of tubular transport defect⁽¹⁸⁾ and of persistent shortening of platelet half-life in nephrotic patients associated with severe form of glomerulonephritis during convalescence or asymptomatic, low-graded proteinuria.⁽³⁶⁾ The mechanism for such tubular dysfunction still remains to be further elucidated. Nonetheless, the presence of marked reduction of peritubular capillary blood flow secondary to the high intrarenal resistance is quite an interesting observation in the severe form of NS associated with FSGS and MPGN.^(25,37) Such reduction of peritubular capillary blood flow and the presence of tubular transporting defect and tubular enzymuria observed simultaneously in this NS may have a spatial relationship.

In relevant to this, renal perfusion in nephrotics is usually deficient in both quality and quantity. Of the former, abnormal blood rheology such as hypercoagulability,⁽³⁸⁻⁴¹⁾ hyperviscosity,⁽³⁶⁾ hyperlipidemia,⁽⁴²⁻⁴⁴⁾ hyperaggregation of platelet⁽⁴⁵⁻⁴⁹⁾ and less deformability of red blood cell due to increased glycosylation of hemoglobin and to lipid peroxidation of erythrocyte have been substantially documented in the NS.⁽⁵⁰⁻⁵¹⁾ Such defective blood rheology would predispose the endothelial cell of the renal microcirculation as well as the tubular epithelium to various injurious triggers known to be

aggravated in the NS namely cytokines,^(52,53) parathyroid hormone,⁽⁵⁴⁾ reactive oxygen metabolites,⁽⁵⁵⁻⁵⁷⁾ platelet activating factor,⁽⁵⁸⁾ oxidized low density lipoprotein⁽⁵⁹⁾ and sensitized mononuclear cell,^(33,34) macrophage⁽⁶⁰⁾ and platelet.⁽³⁵⁻³⁹⁾ Consequence to the activation of endothelial cell, membrane phospholipid is perturbed, degraded, activated and transformed to the procoagulant state with subsequent releases of procoagulant protein namely large von Willebrand factor,⁽⁶¹⁾ tissue factors, plasminogen activator inhibitor⁽⁶²⁾ and various proinflammatory mediators such as eicosanoids, leukotrienes, reactive oxygen metabolites and vasoconstricting mediators such as thromboxane A₂, endothelin and hydroxyeicosatetraenoic acid etc. All of these biopathologic factors would work in favor of the formation of local intravascular coagulation (LIVC) in the renal microcirculation and therefore, further deplete the peritubular capillary blood flow.

These preceding highly intricating agonists would injure the tubular cell as well as the endothelial cell of the microcirculation by increasing transmembrane calcium fluxes.^(63,64) Increased intracellular cytosolic calcium would affect tubular cell functions as are reflected by the enhanced tubular enzymuria in this study and enhanced fractional excretion of solutes in another separate study. Further support that tubular cell injury may plausibly link to the impaired tubular blood flow is derived from the therapeutic observation. In this therapeutic view, improvement in tubular function is documented following the rising of renal blood flow in response to the usage of vasodilators.

Such preliminarily therapeutic benefit with vasodilators renders a suggestive view that hemodynamically mediated trigger may be central to the pathogenesis of tubular injury in this severe form of NS.

Summary

Tubular enzymuria determined as urinary N-acetyl- β -glucosaminidase has been noted to be elevated in both mild and severe forms of NS. During remission, normal value of urinary NAG was observed in mild form of NS, whereas high values of NAG were still observed in one-third of the cases in the severe form of NS. Further reduction of urinary NAG could be achieved with therapeutic vasodilators in this latter group of patients-suggesting a hemodynamically mediated trigger being responsible for the tubular injury.

Acknowledgement

The authors would express a great appreciation to Miss Venus Udomprasertkul for her valuable assistance in statistical analysis.

References

1. Bouisson F, Barthe PH, Pierragi MTH. Severe idiopathic nephrotic syndrome with tubular dysfunction (report of 9 pediatric cases). *Clin Nephrol* 1980 Sep; 14(3): 135-41
2. ter Borg EJ, de Jong PE, Meijer SS, Kallenberg CGM. Tubular dysfunction in proliferative lupus nephritis. *Am J Nephrol* 1991 Jan; 11(1): 16-22
3. Yeung CK, Wong KL, Ng RP, Ng WL. Tubular dysfunction in systemic lupus erythematosus. *Nephron* 1984 Jan; 36(1): 84-8
4. Kozeny GA, Barr W, Bansal VK, Vertuno LL, Fresco R, Robinson J, Hano JE. Occurrence of renal tubular dysfunction in lupus nephritis. *Arch Intern Med* 1987 May; 147(5): 891-95
5. Radovanovic Z, Danilovic V, Velimirovic D, Naumovic T, Jevremovic I, Jankovic S, Vacca C, Hall PW 3d. Beta 2-microglobulinuria as a predictor of death in a population exposed to Balkan endemic nephropathy. *Kidney Int* 1991 Nov; 40 Suppl 34: S32-S34
6. Houser MT, Milner LS. Renal tubular protein handling in experimental renal disease. *Nephron* 1991; 58(4): 461-5
7. Zager RA. Proteinuria of tubulointerstitial nephritis. diagnostic considerations. In: Berlyne GM, Giovannetti S, eds. *Contributions to Nephrology*. Basel: Karger, 1983. 180-90
8. Barratt TM, Crawford R. Lysozyme excretion as a measure of renal tubular dysfunction in children. *Clin Sci* 1970 Sep; 39: 457-65
9. Wilson AT, Hadley WP. Urinary lysozyme III: lysozymuria in children with the nephrotic syndrome. *J Pediatr* 1950 Feb; 36(2): 199-211
10. Fredriksson A, Peterson PA. Effects of renal dysfunction on B2-microglobulin metabolism. *Scand J Urol Nephrol* 1975; 26(1): 61-76
11. Ong-ajyooth S, Ong-ajyooth L, Nilwarangkur S, Sinsakulsak B. Urinary N-acetyl-B-d-glucosaminidase (NAG) isoenzyme in normal and patients with glomerulonephritis. *Intern Med* 1989 Oct-Dec; 5(4): 120-4
12. Kunin CM, Chesney RW, Craing WA, England AC, De Angelis C. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta glucosaminidase in the general population and in patients with renal disease. *Pediatrics* 1978 Nov; 62(5): 751-60
13. Ong-ajyooth S, Ong-ajyooth L, Nilwarangkur S, Sinkakulsak B. Serum and urine N-acetyl- β -d-glucosaminidase (NAG) in patients with glomerulonephritis. *Intern Med* 1986 Jan-Mar; 2(1): 9-13
14. Robinson D, Price RG, Dance N. Rat-urine glucosidases and kidney damage. *Biochem J* 1967 Feb; 102: 533-8
15. Futrakul P, Kullavanijaya P, Watana D, Sensirivatana R, Kwakpetoon S, Unchumchoke, Teranaparin C, Kheokham K. Tubular functions in glomerulonephropathies in childhood. *Internat J Ped Nephrol* 1981; 2(1): 17-21
16. Feng PH, Chan HC, Jacob E, Chio LF, Oon CJ, Siniah R. Tubular functions in lupus nephropathy. A report by Singapore glomerulonephritis study group. *Ann Acad Med* 1977; 6(1): 9-15
17. Murakami T, Kawakami H. The clinical significance of asymptomatic low molecular weight proteinuria detected on routine screening of children in Japan: a survey of 53 patients. *Clin Nephrol* 1990 Jan; 33(1): 12-9
18. Futrakul P, Posyachinda M, Preeyasombatic C, Sensirivatana R, Watana D. Renal tubular defect in nephrotic syndrome associated with focal segmental glomerulosclerosis. *Nephron* 1991; 59(4): 660-1
19. Arbus GS, Poucell S, Bacheyie GS, Baumal R. Focal segmental glomerulosclerosis with idiopathic nephrotic syndrome: three types of clinical response. *J Pediatr* 1982; 101: 40-5
20. Bohle A, Glomb D, Grund KE, Mackensen S. Correlations between relative interstitial volume of the renal cortex and serum creatinine concentration in minimal changes with nephrotic syndrome and in focal sclerosing glomerulonephritis. *Virchows Arch (Path Anat)* 1977 Nov 25; 276(3): 221-5

21. Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H. Longterm prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulo-interstitial changes. *Clin Nephrol* 1990 Mar; 33(3): 115-22
22. Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. *Clin Nephrol* 1991 Jul; 36(1): 53-9
23. Mackensen-Haen S, Bader R, Grund KE, Bohle A. Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. *Clin Nephrol* 1981 Apr; 15(4): 167-71
24. Newman WJ, tisher CC, McCoy RC, Gunnells CJ, Krueger RP, Clapp JR, Robinson RR. Focal glomerular sclerosis; contrasting clinical patterns in children and adults. *Medicine (Baltimore)* 1976 Jan; 55(1): 67-87
25. Futrakul P, Poshyachinda M, Futrakul N, Chaiwatanarat T, Sensirivatana R, Thamaree S, Watana D, Kingwatanakul P. Interarenal hemodynamics alterations and tubular functions in nephrotic syndrome associated with focal segmental glomerulosclerosis (FSGS): a pathogenetic and therapeutic implication. *Proceeding 4th International Sorrento Meeting on Current Therapy in Nephrology. Italy, 1992. (In press)*
26. Wetzels JFM, Hoitsma AJ, Berden JHM, Koene RAP. Renal hemodynamic effects of a short-term high protein and low protein diet in patients with renal disease. *Clin Nephrol* 1988 Jul; 30(1): 42-7
27. de Jong PE, van der Meer J, van des Hem GK, de Zeeuw D. Is the antiproteinuric effect of dipyridamole hemodynamically mediated? *Nephron* 1988; 50(4): 292-4
28. Maruhn D. Rapid colorimetric assay of β -galactosidase and N-acetyl- β -glucuronidase in human urine. *Clin Chim Acta* 1976; 73(3): 453-61
29. Werner M, Masuhn D, Atobal M. Use of gel filtration in the assay of urinary enzymes. *J Chromotogr* 1969 Mar; 40(3): 244-63
30. Buranasiri K, Tosukhowong P, Thamaree S, Chaiyabutr N, Sitprijia V. Urinary enzymes in healthy adults, and in dogs treated with *Russetes viper* venom. *Chula Med J* 1987 Jan; 32(1): 31-6
31. Armitage P. *Statistical Methods in Medical Research.* New York: Halsted Press, 1971. 189-216
32. Armitage P. *Statistical Methods in Medical Research.* New York: Halsted Press, 1971. 394-407
33. Markovic-Lipkovski J, Muller CA, Risler T, Bohle A, Muller GA. Mononuclear leukocytes, expression of HLA class II antigens and intercellular adhesion molecule 1 in focal segmental glomerulosclerosis. *Nephron* 1991; 59(2): 286-93
34. Muller GA, Markovic-Lipkovski J, Muller CA. Intercellular adhesion molecule-1 expression in human kidneys with glomerulonephritis. *Clin Nephrol* 1991 Oct; 36(4): 203-8
35. Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. *Kidney Int* 1990 Feb; 37(2): 783-92
36. Futrakul P, Posyachinda M, Mitrakul C. Hypercoagulability in the nephrotic syndrome: use of anticoagulation. In: *Processing VIIIth International Congress on Nephrology, Athens, 1981. 297-304*
37. Futrakul P, Pochanugoon C, Poshyachinda M, Thamaree S, Yenrudi S, Buranasiri K, Saleekul P, Watana D, Sensirivatana R, Kingwatanakul P, Futrakul N, Panichpun S, Apiwong S, Kwoekpetoon S, Tironaparin C. Intrarenal hemodynamics abnormality in severe form of glomerulonephritis: therapeutic benefit with vasodilators. *J Med Assoc Thai* 1992 (In press).
38. Strauss J, Zilleruelo G, Freundlich M, Abitol C. Less commonly recognized features of childhood nephrotic syndrome. *Pediat Clin North Am* 1987 Jun; 34(3): 591-607
39. Vaziri N. Nephrotic syndrome and coagulation and fibrinolytic abnormalities. *Am J Nephrol* 1983 Jan; 3(1): 1-6
40. Kendall AG, Lohman RC, Dossetor JB. Nephrotic syndrome: a hypercoagulable state. *Arch Intern Med* 1971; 127: 1021-27
41. LLach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. *Kidney Int* 1985 Sep; 28(3): 429-39
42. Kaysen GA. Hyperlipidemia of the nephrotic syndrome. *Kidney Int* 1991; 39(Suppl 21): S8-S15
43. Shore VG, Forte T, Licht H, Lewis SB. Serum and urinary lipoproteins in the human nephrotic syndrome: evidence for renal catabolism of

- lipoproteins. *Metabolism* 1982 Mar; 31(3): 258-68
44. Jungst D, Caselmann WH, Kutschera P, Weisweiler P. Relation of Hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome. *Clin Chim Acta* 1987 Sep 30; 168(2): 159-67
45. Kanfer A, Kleinknecht D, Broyer M, Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. *Thromb Diath Haemorrh* 1970 Dec; 24: 562-71
46. Panicucci F, Sagripanti A, Vispi M, Pinori E, Lecchini L, Barsotti G, Giovanetti S. Comprehensive study of hemostasis in the nephrotic syndrome. *Nephron* 1983; 33(1): 9-13
47. Yoshida N, Aoki N. Release of arachidonic acid from platelet. A key role for potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. *Blood* 1978 Nov; 52(5): 969-77
48. Cameron JS. Platelets and glomerulonephritis. *Nephron* 1977; 18(5): 253-8
49. Machleidt C, Mettang T, Starz E, Weber J, Risler T, Kuhlmann U. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. *Kidney Int* 1989 Dec; 36(6): 1119-24
50. Cecchi E, De Marchi S, Panarello G, De Angelis V. Rheological abnormalities of erythrocyte deformability and increased glycosylation of hemoglobin in the nephrotic syndrome. *Am J Nephrol* 1987 Jan; 7(1): 18-21
51. Clemens MR, Bursa-Zanetti Z. Lipid abnormalities and peroxidation of erythrocytes in nephrotic syndrome. *Nephron* 1989; 53(4): 325-9
52. Sobel At, Heslan JM, Branellec A, Lagrue G. Vascular permeability factor and other lymphokines in nephrotic syndrome. In: Brodehl J, Ehrich JHH, eds. *Pediatric Nephrology*. Berlin: Springer-Verlag, 1983. 264-6
53. Maruyama K, Tomizawa S, Shimabukuro N, Fukuka T, Joshita T, Kuroume T. Effects of supernatants derived from T lymphocytes culture in minimal change nephrotic syndrome on rat kidney capillaries. *Nephron* 1989 Jan; 51(1): 73-6
54. Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. *J Clin Endocrinol Metab* 1981 Jan; 52(1): 116-21
55. Rahman A, Johnston KJ, Wiggins RC, Kunkel RG, Ward PA. Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. *Lab Invest* 1984; 51: 396-403
56. Diamond JR, Bonventre JV, Karnovsky MJ. A role for oxygen free radicals in aminonucleoside nephrosis. *Kidney Int* 1986 Feb; 29(2): 478-83
57. Thakur V, Walker PD, Shab SV. Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria. *Kidney Int* 1988 Oct; 34(4): 494-9
58. Perico N, Remuzzi A, Dadan J, Battaglia C, Remuzzi G. Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. *Am J Physiol* 1991 Jul; 261(1pt2): F85-F90 (*Renal Fluid Electrolyte Physiol* 30)
59. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. *Proc Natl Acad Sci USA* 1987 May; 84(9): 2995-8
60. Magil AB, Frohlich JJ. Monocytes and macrophages in focal glomerulosclerosis in Zucker rats. *Nephron* 1991; 59(1): 131-8
61. Ono T, Kanatsu K, Doi T, Sekita K-I, Onoe C, Nagai H, Muso E, Yoshida H, Tamura T, Kawai C. Ultrastructural distribution of von Willebrand factor in human glomerular disease. *Nephron* 1989; 53(4): 311-6
62. Wiggins RC. Role of coagulation in glomerular and vascular diseases. In: Massry SG, Glasscock RJ, eds. *Textbook of Nephrology*. Vol. 1 Baltimore: Williams & Wilkins, 1989. 572-7
63. Leat A, Macknight ADC, Cheung JY, Bonventre JV. The cellular basis of ischaemic acute renal failure. In: Andreoli TE, Hoffman JF, Fanestil DP, Schulta SG, eds. *Physiology of Membrane Disorders*. New York: Plenum, 1986. 769-84
64. Weingerg JM. The cell biology of ischaemic renal injury. *Kidney Int* 1991 Mar; 39(3): 476-500